BPC-157 near me: what local clinics charge and leave out

By Peptide Care Index

Searching for BPC-157 near me turns up clinic advertisements, not confirmed access. No FDA-approved BPC-157 medicine was identified in the records reviewed, and it is absent from the final 503A bulk-ingredient list. Before paying specifically for a product, get its identity, pharmacy, supply basis, and full fees in writing; judge a general consultation separately. FDA evaluation, p. 9; current 503A list.

We read pages from six local clinics in five states. None identified a pharmacy specifically assigned to BPC-157 orders. Only two posted a BPC-157 price. Below is what they show, what they skip, and the exact message to send a clinic near you to ask for the missing answers before you pay.

Where to start depends on what you already have:

Source: See the cited records and links in the Sources section below.

If you're a drug-tested athlete: BPC-157 is prohibited at all times under the World Anti-Doping Agency's list; a prescription does not by itself remove that restriction. Read this first. See also the WADA banned peptides table for category and effective-year distinctions.

BPC-157 near me: what 6 local clinic pages actually show

The clinic pages we reviewed promote care but leave material purchase questions unanswered. In the six-clinic page set we read on October 15, 2026, none identified a pharmacy specifically assigned to BPC-157, two posted a product price, one posted its consultation fee, and two included a BPC-157 non-approval statement. Use their gaps as your checklist for any clinic near you.

The six-clinic set came from the search research used to prepare this guide, including a Houston page written around "BPC-157 near me." For this review, we re-read the clinics' service pages and the related pricing, pharmacy, or policy pages identified below. The order is preserved from that comparison; it is not a nearest-clinic list or a current search-ranking order. This is not a ranking, a recommendation, or a sample of every clinic. Each finding applies only to the cell it's in.

Pages from six local clinics offering or describing BPC-157 — provider-published statements, checked October 15, 2026

Source: each clinic's own pages, linked in the table, read October 15, 2026. A missing item means it was not established in this page set—not that the clinic can never provide it. These are what the clinics say about themselves. We did not call clinics, check licenses, buy products, or confirm that any clinic can supply BPC-157 to you.

What the six-clinic page set shows (our counts from the table, not a market-wide survey):

• 0 of 6 identified a pharmacy specifically assigned to BPC-157 orders. One clinic linked a partner-pharmacy page that named a Florida pharmacy for a Nevada clinic.
• 2 of 6 posted a BPC-157 price, and their units didn't match: one priced a 10 mg bottle, the other priced a "vial" without saying how much it holds.
• 1 of 6 posted its consultation fee.
• 2 of 6 included a BPC-157 non-approval statement; Robertson qualifies its wording as not approved for a specific injury, while Back On Point's main-page FAQ says it is not an approved drug.
• 0 of 6 explained the distinction between the July advisory recommendation and addition to the final 503A bulk-ingredient list in the inspected page set.
• At least 3 of 6 used broad healing claims such as "highly effective," "dramatically accelerates," or "accelerating the body's natural healing." The human reports below do not establish those broad outcomes for their advertised products. This is an editorial claim check, not a clinical score.

A clinic page is an ad, and that's fine — but in this comparison, important facts were still missing. Those facts are the product amount, who makes it, the whole bill, and what happens if nothing is filled. Ask for them in writing. A question the clinic cannot answer stays unresolved.

A worked example: what $505 does and doesn't cover

Robertson Wellness publishes two numbers: a $350 required consultation and $155 for a 10 mg bottle of BPC-157. Our arithmetic: $350 + $155 = $505 for one consultation and one bottle.

That is not a monthly cost and not a full bill. The page says blood work "may be needed" at extra cost, doesn't say how long a bottle is meant to last, and doesn't name who prepares it. A charge you haven't seen yet is unknown, not zero.

Why we name these clinics

These are public pages that people find when they search for BPC-157 near them. Naming and linking them lets you check our reading against the source. A clinic that has updated its page can send the new source through our contact and corrections page.

If you already have a clinic in mind, the next step depends on the exact product, who fills it, and which answers are still missing. Use Peptide Care Index's Find My Peptide Path tool to work through the BPC-157 access evidence, the provider checks, and the questions to ask before you pay. It's free, needs no signup, and gives you questions and evidence — not a prescription or a clinic match.

Find My Peptide Path

Is it legal for a clinic near you to offer BPC-157 right now?

No FDA-approved BPC-157 medicine was identified in this review, and BPC-157 is absent from the final 503A bulk-ingredient list. The eCFR page displayed Title 21 current through October 13, 2026 when checked on October 15; that is a version date, not a new BPC-157 decision. An advisory recommendation is not a list addition or product approval. The current basis for a particular pharmacy to supply a particular preparation remains unresolved in this review, so a clinic offering it should explain the basis it relies on. FDA evaluation; 503A framework.

That answer has three parts, and clinics often blur them together. Here's what changed in 2026, in order.

BPC-157 compounding status: what each 2026 step did and didn't do

Source: See the cited records and links in the Sources section below.

For more dated FDA records, see our BPC-157 news and evidence tracker and the BPC-157 FDA status explanation.

The vote count is attributed to reporting; we did not retrieve an official roll call. The original April notice was not retrieved separately, so its announcement date and seven-day timing remain attributed to Orrick. The current FDA records—not those reports—support the present list and safety findings. We identified no issued BPC-157-specific stopgap in the official records and targeted FDA/HHS searches checked on October 15; that is the scope of the check, not a claim to have searched every possible agency document.

Three words clinics mix up

• FDA-approved means FDA reviewed a finished medicine for safety and effectiveness. No approved BPC-157 medicine was identified in the records reviewed.
• Compounded means a medicine was prepared or altered for a medical need. Federal law addresses pharmacy and physician compounding and a separate outsourcing-facility framework. Compounded finished products are not FDA-approved, even when compounding them is allowed (FDA).
• Off-label means using an already-approved drug in a way its label doesn't cover (FDA). It doesn't fit BPC-157, because there's no approved BPC-157 drug to use off-label.

Can a doctor prescribe BPC-157—and can the pharmacy fill it?

Some clinics advertise BPC-157 after clinician review. But a clinician's willingness to consider it does not settle whether a pharmacy can prepare and supply the exact product. Before paying for a visit solely to obtain BPC-157, separate the medical evaluation from the proposed fill. Example of an advertised workflow; FDA compounding framework.

There are three different decisions: what care is appropriate, whether a prescription is written, and whether the pharmacy can fill it. A useful consultation can end without a prescription. A written order also leaves pharmacy and product questions to resolve.

For traditional compounding from a bulk ingredient, section 503A sets ingredient conditions as well as other requirements. In plain terms, the ingredient conditions concern an applicable USP or NF monograph—an official drug-quality standard—or, when no monograph applies, an ingredient in an approved drug or a substance on FDA's final 503A bulk-ingredient list. The final list is therefore not an inventory of every ingredient used in all compounding. FDA's 503A framework.

For the two BPC-157 forms evaluated, free base and acetate, FDA's May staff briefing identifies no applicable monograph or approved-drug component. FDA separately describes an interim enforcement policy for certain nominated substances. That policy is not the same thing as finished-product approval. BPC-157 does not appear in Category 1 in the May 14, 2026 nomination-list PDF inspected. We have not resolved how the policy applies to a particular clinic's proposed preparation. FDA evaluation, p. 9.

A 503B outsourcing facility operates under a different framework, including its own bulk-substance requirements. Calling a facility “503B registered” does not answer whether a particular bulk ingredient meets its requirements; that claim needs its own supporting basis. FDA's separate 503B framework.

Our access check, requirement by requirement

Which federal records answer which access question? Checked October 15, 2026. This does not determine the legal status of an individual transaction.

Source: See the cited records and links in the Sources section below.

If a clinic says BPC-157 is "legal again"

Ask one question: "Which current FDA action or policy covers this exact BPC-157 product, and which pharmacy will fill it?"

A headline, a podcast remark, or the July vote doesn't answer that. If HHS announces the reported stopgap, the answer may change — and a clinic should be able to name it and its date. A report of a proposed plan is not the policy itself. "Legal again" is a claim to check against an actual action, not a fact to assume.

Local BPC-157 access check: from a map result to written answers

Before you book, separate three things: the visit, the product, and the pharmacy that fills it. A map listing gives you a candidate business and address; it doesn't confirm who will see you, what you'd receive, or who makes it. Use this check to turn a nearby listing into written answers, one requirement at a time.

Find candidates without mistaking a map result for proof

Search for BPC-157 or peptide therapy plus your city, and you'll see wellness clinics, med spas, chiropractors, hormone clinics, and sports-medicine practices. That list is a starting point.

For each one, open the clinic's own service page. Check whether the visit happens in person at that address or by video. Then get the name and role of the person who would evaluate you. Don't assume stock, appointment times, or state coverage from a search snippet or a star rating.

If you already see a clinician you trust, you can start there instead of shopping for a new clinic.

The check

Local BPC-157 access check — use one row per question; a "yes" on one row doesn't settle the others

Source: See the cited records and links in the Sources section below.

If two source statements answer the same question differently, mark that row Conflicting, not "fine." A price labeled for a different peptide is instead Not applicable to a BPC-157 quote. The laboratory-report example below shows a genuine conflict about which reports are available.

Green, yellow, and red signals

These are communication and payment signals, not safety grades, legal rulings, or a provider score. A green entry answers one question; it does not cancel an unresolved question in another row.

Source: See the cited records and links in the Sources section below.

Med spas, gyms, and coaches

Who may evaluate you, prescribe, or administer a product depends on the professional role and applicable state rules. At a med spa, ask who is responsible for the medical evaluation, who would administer any treatment, and what authorization or supervision applies. Start with the relevant state medical board or nursing board; this review did not perform individual license or state-law checks.

A gym, coach, or spa offering a vial has not documented a medical-care arrangement merely by having a storefront. Ask who evaluates you and who prepares or supplies the product. Direct dispensing and supervision rules vary; the venue alone does not establish that an offer is either authorized care or a research-product transaction.

Name the product before judging the offer

“BPC-157” alone does not fully identify an offer. Ask for the ingredient form, how it would be administered, labeled strength, quantity, and any other active ingredients.

Free base, acetate, and a product advertised as another salt should not silently inherit each other's documentation. A swallowed capsule is not a sublingual strip used under the tongue. BPC-157 alone is also different from a blend containing another peptide. FDA's briefing itself distinguishes the evaluated forms and discusses naming concerns. FDA evaluation, pages 8–10.

Here, strength and quantity help you identify what is being offered. They are not instructions about how much you should use. Ask for a product description detailed enough to compare with the eventual label and bill.

For a separate reference, see what the exact product's storage instructions do and do not show.

What one offer and its laboratory report actually prove

A laboratory report can answer a narrower question than the sales page surrounding it. Read the report's sample, tests, and results before deciding what the claim means.

We selected Rx Peps Direct as a document-reading example because its BPC-157 offer publishes an exact product specification, itemized charges, and a report link. This is an unpaid example, not a provider ranking or recommendation.

The linked Eagle Analytical Services report ETX-260727-0539 identifies Optimal Balance Pharmacy, sample BPC-157 3 mg/mL, 5 mL, and lot LG342009607. Testing was completed July 31, 2026. It reports a ScanRDI sterility-test pass and a bacterial-endotoxin result below 2 EU/mL, marked pass. Endotoxins are bacterial components; EU/mL is the test's reporting unit, not an instruction about an amount to use.

The results concern the submitted sample. The report does not show an identity or potency assay on that page, and its product description is not itself such a test. We inspected the provider-hosted PDF; we did not authenticate it with the laboratory or test a product ourselves.

Offer and report check: specific findings, not a “verified supplier” badge. Checked October 15, 2026.

Source: See the cited records and links in the Sources section below.

The practical lesson is not “all testing claims are useless.” A report can provide useful, specific information. The mistake is allowing one answered question to stand in for all the unanswered ones.

For any certificate of analysis, check the laboratory name, tested substance, lot, methods, dates, and actual results. Ask whether identity, amount, impurities, sterility, or endotoxin was tested rather than assuming a purity percentage covers everything. This is a way to read evidence, not a method for making a research-use vial suitable for personal treatment.

FDA's online-pharmacy guidance points to a prescription requirement for prescription medicine, U.S. contact information, access to a licensed pharmacist, and state-board licensing. Those checks concern the professional or business. Even an active license does not independently establish BPC-157 approval, treatment benefit, the contents of a particular vial, or permission to use any bulk ingredient. We did not perform individual license checks for this article.

Local clinic, in-state telehealth, or online review: which fits?

For BPC-157, "near me" involves both the visit and the professionals authorized to provide it. The clinician must be licensed in, or otherwise allowed to practice in, the state where you are during the visit — whether you're in their office or on a video call (HHS). An in-person appointment can allow a physical exam and hands-on help; confirm what the booked service includes. The address doesn't make the product better or the supply basis clearer.

Ways people look for BPC-157, compared (not ranked)

Source: See the cited records and links in the Sources section below.

How to get BPC-157: compare the access routes

The route matters more than whether a website accepts payment. A clinic advertisement can establish what is being offered, while a study record can describe a research opportunity. Neither, by itself, confirms that you can receive a particular BPC-157 product.

BPC-157 access routes: what the reviewed evidence establishes, as of October 15, 2026.

Source: See the cited records and links in the Sources section below.

“Not verified” describes the limits of our review. It does not mean nobody advertises or supplies BPC-157, or that every possible arrangement has been investigated.

Related seller records: FDA warning letters to peptide sellers.

Your product needn't be made near you

The clinic you visit and the pharmacy that makes your product can be different businesses, even in different states.

Look at the Las Vegas example in the table above. The clinic offers in-person visits in Summerlin, but the one partner pharmacy it lists is in Miami. Its page doesn't say whether that pharmacy fills BPC-157. A short drive to the clinic tells you nothing about where the product comes from.

So ask for the pharmacy's legal name and state. Then look it up through your state pharmacy board using FDA's lookup page. A license shows the pharmacy may operate. It doesn't, by itself, show that BPC-157 may be compounded or that a vial contains what the label says.

Crossing a state line

Here's a hypothetical. You live in Idaho. The closest clinic advertising BPC-157 is across the border in Washington. You drive over for an in-person visit.

That visit happens in Washington, so the clinician must have the relevant authorization to provide that care there. A license alone does not establish authority to supply BPC-157. When you're back home and do a follow-up video call, you're in Idaho. The clinician needs the relevant Idaho license or other applicable authorization for that call, and the pharmacy must be able to serve Idaho. HHS explains the different authorization routes; this example is not a state-specific legal determination.

Before you drive, ask in writing: "Can follow-up visits continue after I'm home, and can the pharmacy ship to my state?"

Start with the problem, not the peptide

If you have a sore tendon, a slow-healing injury, or gut symptoms, the most useful local visit is one that figures out what's wrong and compares the treatments with stronger evidence. You can still bring up BPC-157 at that visit. The visit has value even if nothing about BPC-157 comes of it.

You can take this question to a clinician you already see:

What human evidence applies to my goal and the exact BPC-157 form being discussed? What established options should we compare? What would this appointment cover if BPC-157 is not prescribed or cannot be supplied?

That keeps the visit focused on the problem you want help with, rather than making the prescription itself the measure of success.

What does BPC-157 cost at a clinic near you?

The local pages in our six-clinic sample did not establish a complete patient-specific BPC-157 bill. In that sample, one clinic posted $155 for a 10 mg bottle plus a required $350 consultation. Another posted "starting at $250 per vial" without the vial size or visit fees. Ask whether the visit, product, labs, and follow-ups are charged separately — and treat any required charge you haven't seen as unknown, not zero.

The parts of a BPC-157 bill

• The visit. A consultation fee; ask whether it remains payable if nothing is prescribed.
• The product. The price depends on the form, strength, and amount, so a price without the amount can't be compared.
• Labs. Blood tests, sometimes required and sometimes optional.
• Follow-ups. Later visits or messages, sometimes billed separately.
• Supplies and shipping. Syringes, cold packs, and delivery.
• Membership. Some clinics bundle care into a monthly plan.
• Renewals. Refills that charge again automatically.
• Refunds. What you get back if nothing is prescribed or the pharmacy can't fill the order.

Published BPC-157 price examples, U.S. dollars — side by side, not ranked

Sources: each provider's own published pages. Provider-published prices; we didn't get a personal quote or complete a purchase.

A separate Spokane example—not part of the six-clinic count—shows why the fee label matters. The Lab Aesthetics & Wellness lists a $99 initial consultation, $150 initial labs, and BPC-157 at $300 for one month. It separately lists NAD+ at $300 for three months; those are different entries. Our calculation: $99 + $150 + $300 = $549 only if all three charges apply together. The page does not establish the exact BPC-157 formulation, quantity, complete inclusions, individual requirements, amount charged now, renewal terms, or no-fill policy. This is a conditional subtotal, not a matched package or a complete quote. Checked October 15, 2026.

It's tempting to divide by milligrams: $155 ÷ 10 mg is $15.50 per mg, and $80 ÷ 15 mg is about $5.33 per mg. But that math hides real differences. The visit fees differ, the services differ, and you'd be comparing a product from an unnamed pharmacy with one from a different arrangement. So the per-milligram figure doesn't tell you which offer is the better deal or the better care.

That gap doesn't prove local clinics charge more, either. These are different products and services, not matched packages. For more published prices, see BPC-157 cost and our peptide price list.

One advertised order: $134 in disclosed charges, not a monthly cost

The inspected offer provides enough information to add three stated charges for one order. That arithmetic does not establish a treatment duration, individual eligibility, or a complete patient-specific quote.

Rx Peps Direct example, U.S. dollars; provider-published terms checked October 15, 2026.

Source: See the cited records and links in the Sources section below.

Our calculation: $39 + $80 + $15 = $134. The labeled amount is 3 mg/mL × 5 mL = 15 mg; this identifies the vial, not a personal dose.

Do not label that sum “per month.” We did not establish whether your evaluation would require additional tests or services, any applicable extra charges, or their cost. A required item left unpriced would make your complete total unknown, not zero. Nor does this sum mean one business collects every charge at the first step.

What happens if nothing is prescribed or filled

A clinic can keep its visit fee even when no prescription follows, and that's often fair — you paid for an evaluation. But the clinic's policy doesn't tell you what the pharmacy will do if it can't fill an order. Ask both businesses.

The service-page comparison does not establish that a clinic has no refund policy. Modern Wellness links a return and refund policy: it says no refunds after a service is performed or a prescription is approved; dispensed medications are nonrefundable, with exceptions reviewed case by case. It requests at least 24 hours' notice to reschedule and says missed appointments or late cancellations may carry a fee, without stating that fee. Its wording does not separately resolve every charge if a prescription is approved but never filled. Ask that exact question before paying. These are provider-published terms, not our determination of their legal enforceability.

The online example below makes the distinction between the review service and the pharmacy equally important.

Rx Peps Direct's medical-review policy and refill terms — provider-published scenarios, checked October 15, 2026.

Sources: Refund and Cancellation Policy, updated June 2026; Terms of Service, updated March 2026. These are the provider's stated terms, not a legal determination about an individual refund claim.

A consultation can have value even when no prescription follows. The important question is whether you understand the service you are buying—and would still consider it worthwhile without receiving the product.

Will insurance or an HSA pay?

This review did not establish coverage or reimbursement under your plan. Modern Wellness says peptide therapy usually isn't covered. A covered office visit doesn't mean the product is covered.

Ask your insurer or plan administrator about the visit, the tests, and the product separately. A card being accepted at checkout doesn't mean the expense qualifies for a health savings or flexible spending account.

A first price is one line of the bill. Find My Peptide Path lays out each charge to ask about — the visit, the product amount, labs, renewals, and what you'd owe if nothing is filled — so you can compare a local quote fairly and spot the missing piece.

Find My Peptide Path

The message to send a clinic near you

You can ask for every missing answer with one written message. Send it to the clinic you're considering before you book, and keep the reply with your quote. You don't need to share your medical history to ask.

Copy-and-send message

Hi — before I book, could you send these answers in writing?

1. Will my visit be in person at your listed address or by video? Who would evaluate me, and what is their role and license or other state authorization? If I'm seen in person, can follow-up visits continue after I'm back in my home state?
2. What exact BPC-157 product would you consider? Please list the exact ingredient form (for example, free base, acetate, or another stated salt), how it's taken, the strength, the amount, and any other active ingredients.
3. Which pharmacy would fill it, what state is it in, and can it ship to my state?
4. What current rule, policy, or agency action do you rely on to supply this exact preparation, and how does it apply to the pharmacy or other supplier?
5. Please itemize what I'd pay now and to which business: consultation, product, required labs, follow-ups, membership, shipping, and anything that renews or requires a minimum commitment.
6. What would I owe if no prescription is written, or if the pharmacy can't fill the order? What changes if a different product or pharmacy is used? Please include the retained or refundable amount for each business, cancellation deadlines, and the clinical, pharmacy, and billing contacts for help afterward.

Thank you!

BPC-157 clinic check: before you book or pay

Ask before paying — and what a useful written answer includes

Source: See the cited records and links in the Sources section below.

A required test with no price means the total is unknown — not that the test is free. A "monthly" figure doesn't tell you whether several months are charged up front. Ask for the amount charged today and the minimum commitment, side by side.

What if there's no BPC-157 clinic near you?

You don't need a clinic down the street. A telehealth clinician licensed or otherwise authorized where you will be can provide care within that service's scope, and the same written checks apply. A remote visit does not provide every kind of physical examination. HHS state-service guidance. If no clinician you trust can answer the supply questions, the better move is a regular visit about the underlying problem — not a research-use vial.

• Ask a clinician you already see. They may not offer BPC-157, but they can evaluate the problem and talk through evidence and other treatments.
• Use appropriately authorized telehealth. Check the clinician's authorization where you will be during the visit, and get the pharmacy's name before paying for a product.
• Don't substitute a "research use only" product. That label means the seller says it isn't for people. The label does not document a patient-care arrangement or pharmacy dispensing. A purity percentage on its website doesn't answer whether it's suitable for human treatment. We don't cover or recommend these sellers.
• Don't count on an overseas seller. FDA says bringing unapproved drugs into the U.S. for personal use is generally not allowed. It considers only limited cases, so this isn't a blanket small-order exemption (FDA personal importation).

Trials near you

A clinical trial is research, not a treatment appointment. In the four selected BPC-157 records reviewed, the U.S. rotator-cuff study was not yet recruiting and the other U.S. study was completed. No study team confirmed enrollment for this review.

Focused BPC-157 study-access register, checked October 15, 2026. These are four selected full ClinicalTrials.gov records, not a search of every registry or unpublished study.

Source: See the cited records and links in the Sources section below.

Estimated enrollment is a target, not the number already treated. “No posted results” means outcomes were not posted in the inspected registry record; it does not prove no other results exist. The oral-tablet record includes an unposted submission event in May 2016, so “no posted results” should not be rewritten as “results were never submitted.”

The Arkansas record needs particular care. Its summary says 20 participants, while the enrollment field says 30. One description specifies saline injections for the comparison group, while another describes no injections or treatment. Those are meaningful differences in what participation could involve, not details to quietly smooth over.

The hamstring record's narrative describes BPC-157 versus placebo, but its structured arm fields associate both interventions with both arms. The older oral record's narrative places the study in January–June 2015, while its structured fields give a later start and estimated completion. The linked full records let you inspect these conflicts yourself.

For the broader evidence record, see what the human studies actually show.

How to check a study before making plans

Read the full record, then confirm the current situation with the official study team. A promising title, estimated start date, or “FDA-regulated drug” field is not approval or an invitation to enroll.

1. Match the population. Read the condition and eligibility criteria. General interest in recovery is not the same as having the specific injury or surgery described.
2. Check the location and status together. Note the country, site, last update, and whether recruitment has actually started.
3. Look for internal disagreements. Compare the summary, enrollment, treatment groups, and dates rather than reading only the headline.
4. Use the official contact. Ask the listed study team whether it is recruiting, what participation involves, whether a comparison group is possible, and which costs or travel commitments apply.

A paid clinic visit doesn't enroll you in any of these studies. Participation may involve a comparison treatment and does not guarantee BPC-157 or benefit. The study team, not this article or the Path resource, determines eligibility.

Is expanded access another option?

FDA's expanded-access framework concerns certain serious or immediately life-threatening conditions when satisfactory alternatives are lacking and trial participation is not possible. It requires more than a patient request, including participation by the treating clinician and the company providing the investigational product, along with applicable review requirements. FDA's information for patients.

All four inspected study records indicate no listed expanded-access offering. We did not verify a BPC-157 expanded-access program. The general framework is therefore not a documented routine option for this guide, and meeting its broad description would not guarantee supply.

What to know about BPC-157 before you book

Most BPC-157 research is in animals; the human evidence below includes small clinical reports and a larger clinical-note preprint, none with a treatment comparison group. So no clinic can honestly promise healing. FDA lists concerns about immune reactions, impurities, and limited human safety information. None of that proves BPC-157 never helps — it means your visit should cover the expected benefit, the alternatives, and the follow-up plan. FDA review; FDA safety entry.

Here's what the human evidence looks like in practice.

Selected human evidence on BPC-157 — what was studied and what it can't tell you

Sources: the original reports linked in each row, read for this audit on October 15, 2026; relevant pages of the knee and IV PDFs were visually inspected. The preprint remains version 1 on the inspected page. Its researchers used language-model-assisted extraction of clinical notes with sampled validation—not a clinical examination of every reported user. Our percentages are calculated from the counts in that preprint. See also the BPC-157 news and evidence tracker. This is a selection, not a census of every human study. FDA's May 2026 review also describes earlier small human studies, including a bowel-disease study known only from a meeting abstract (FDA, Appendix 1).

The knee series is a signal worth describing honestly, not a reliable success rate you can apply to yourself. Without a comparison group, the study cannot separate a peptide effect from natural recovery, other care, expectations, or differences in who reported back. Reported improvement is not objective proof of repaired tissue.

The combination patients are a separate group. Four of the 16 patients reached in the knee series received BPC-157 plus a substance the authors call TB4. We do not relabel that as a verified TB-500-fragment study or use it to endorse a blend. Original knee report.

FDA's safety page says compounded BPC-157 may trigger immune reactions for some routes of administration. It also flags peptide impurities and says FDA found little or no safety information for the proposed routes (FDA). On October 13, 2026, KFF Health News published patients' accounts of harm involving experimental peptides, including BPC-157 (KFF Health News). Those are reported experiences, not a side-effect rate.

Does the form matter? Yes. A capsule you swallow, a strip under your tongue, and an injection under your skin are different products with different evidence. A study of knee-joint injections doesn't carry over to capsules. Some clinic pages describe injections; others leave the form unclear. If a clinic offers capsules, see BPC-157 capsules and oral evidence.

Do capsules, strips, or injections change the answer?

Changing the form changes which product and evidence you need to inspect. It does not make research about one formulation apply to another, or settle whether the advertised product can be supplied as treatment. A product you can order is not necessarily a product whose claimed benefit has been established.

A swallowed product goes through the digestive tract; a sublingual preparation is intended for use under the tongue. Injections also differ by where the product is delivered. Those distinctions matter when a sales page cites a study.

Source: See the cited records and links in the Sources section below.

This is a way to read the claims, not a recommendation to choose a particular form. FDA's observation that capsules and tablets are marketed does not approve them or settle a particular product's supplement status. FDA briefing, page 9.

If you feel unwell after using any product, contact a clinician; urgent symptoms need urgent care. Bring the label, lot number, and seller details.

Athletes, people who already have BPC-157, and other exceptions

A few situations change the answer even when a clinic is nearby. Check yours before paying.

• You're subject to drug testing. The World Anti-Doping Agency lists BPC-157 under S0, prohibited at all times, in and out of competition. It is also named in the 2027 list, p. 4, effective January 1, 2027. A prescription does not by itself remove the restriction. Check your own sport's anti-doping rules.
• You already have a prescription or product. Ask the prescriber and the dispensing pharmacist to confirm the label matches what was discussed: the form, strength, pharmacy, and lot. Don't use an article as instructions to change or swap a treatment.
• The clinic won't name the pharmacy or price. Treat that as unresolved. It isn't proof of anything wrong, but it isn't a good answer either. We'd hold off on a product-specific payment until you have it. A general medical evaluation can still be worth booking on its own terms.
• You live outside the U.S. This page covers U.S. rules only. Your country's rules may differ.

How we checked

We read the six-clinic page set and the linked pricing, pharmacy, and Modern Wellness refund pages on October 15, 2026, and compared what each publishes with what a buyer needs to know. We also checked the separate Spokane and online examples, the federal records, selected original human reports, and four complete trial records on October 15. This is a source review, not a clinical, legal, or pharmacy inspection.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

What we actually checked

• Clinic and offer records: the six-clinic service-page set; the linked Endocrinology Associates pricing and BPC-157 pages, Back On Point main-page FAQ, and Modern Wellness pharmacy and refund pages; the separate Spokane price menu; and Rx Peps Direct's offer, refund policy, terms, and linked laboratory report. All were read October 15, 2026. Advertisements were not converted into verified fulfillment or clinical claims.
• Federal records: FDA's May BPC-157 staff evaluation, including the approval/monograph statement on printed page 9, and the committee briefing; FDA's current safety-risk page; its nomination-list PDF updated May 14, 2026; the complete positive list in 21 CFR 216.23(a), displayed current through October 13; the 503A/503B explanations; and the July meeting page. We also performed an exact-name Drugs@FDA-derived API query and an exact-phrase Federal Register API search on October 15. Those searches have the name and database limits stated here. April announcement timing and the July vote tally remain attributed to the identified reporting; no original April notice or official roll call was retrieved separately.
• Other records: four complete ClinicalTrials.gov records, including sponsor, country/site, recruitment, enrollment, dates, results availability, and conflicting fields; the original knee and IV reports and the September preprint; WADA's current online list and the 2027 list PDF; HHS telehealth guidance and official licensing lookup routes. The relevant FDA, research, laboratory, and WADA PDF pages were visually inspected. The laboratory report was not authenticated with its issuer.
• What we didn't do: call or email clinics; check any individual license; inspect pharmacies; buy or test products; confirm a fill or a personal quote; confirm study enrollment; or get legal advice. Reading licensing guidance is not performing a license check. A source-check date is not the publication or modification date of this article.
• Review: this work used AI assistance. No clinician, pharmacist, or regulatory specialist reviewed this page. See our editorial and AI-assistance standards.

How to read a finding. The Peptide Care Access Check looks at one requirement at a time. For each one it sets out the evidence, the check we did, the finding, the next question, and what would change the finding. It never gives an overall safety score or a "verified clinic" badge.

• Supported: the source backs that exact statement — for example, a clinic's published $155 price.
• Contradicted: the source shows the requirement isn't met — for example, BPC-157's absence from the final list.
• Unresolved: the evidence doesn't settle it — for example, which pharmacy would fill an order.
• Conflicting: two statements answer the same question differently — for example, an offer links a standalone laboratory report while its later FAQ says only combination reports are on file.
• Not applicable: the evidence can't answer that question — for example, a lab report offered as proof that a product works.

The six clinics were carried forward from the search-research sample, not selected because they paid or ranked first. Current provider citations are unpaid. Read our methodology and how we make money. Our homepage's provider comparison is a separate, alphabetical comparison of online care terms, not a list of BPC-157 suppliers.

Your next step

If you have a clinic in mind, send the message above and wait for written answers before paying for a product. If you don't, start with a clinician appropriately authorized where you will receive care who can evaluate the problem you want fixed. Either way, the goal is the same: know what you'd get, who makes it, and what it costs before money changes hands.

Take the clinic's answers — or its gaps — to Find My Peptide Path. It sets out the dated BPC-157 access evidence next to the provider and fee questions, so you can see what's settled and what you still need to ask. It's free, needs no signup, and doesn't promise a prescription or a clinic match.

Find My Peptide Path

Questions people still ask

Can I buy BPC-157 at a pharmacy near me without a prescription?

This review did not verify a routine prescription-free BPC-157 pharmacy route. No FDA-approved BPC-157 medicine was identified. Patient-specific 503A compounding and 503B outsourcing have different requirements, so neither a pharmacy sign nor an available vial establishes access. Ask the pharmacist about the exact product and supply basis, rather than assuming a walk-in purchase is permitted. FDA compounding framework.

Is a BPC-157 clinic near me more trustworthy than an online one?

Not automatically. A local appointment can offer an in-person exam, but the product can come from a different pharmacy, including one in another state. Judge any clinic, local or online, by the same written answers: clinician, product, pharmacy, supply basis, and full price.

Did FDA approve BPC-157 in July 2026?

No. ABC News reported an 8–6 advisory vote, with one abstention, recommending addition of BPC-157-related substances to the compounding list. That advice is not product approval, and BPC-157 remained absent from the final 503A list inspected October 15, 2026 (ABC News; eCFR).

Does a med spa need a doctor or nurse practitioner to give BPC-157?

Professional scope and supervision rules depend on the state and the people involved. Ask who performs the medical evaluation, who prescribes or administers the product, and what authorization or supervision applies. The words "med spa" do not establish those answers or the product's supply basis. Use the official board lookup routes.

Is there a BPC-157 study near me?

The four records reviewed did not establish an open U.S. enrollment option. The Little Rock, Arkansas rotator-cuff record was not yet recruiting, with an estimated start of January 1, 2027; the U.S. gummy study was completed. Neither an estimated start nor this article establishes your eligibility (NCT07803250).

Related research: BPC-157 in the peptide search ranking.

Related safety research: peptide side effects chart.

Sources

All checked October 15, 2026, unless another date is shown.

1. U.S. Food and Drug Administration. BPC-157 staff evaluation for the July 23–24, 2026 Pharmacy Compounding Advisory Committee. Dated May 11, 2026; page 9 (approval and monograph statement); Appendix 1. Checked October 15, 2026.

2. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document. Staff proposal not to add BPC-157.

3. U.S. Food and Drug Administration. Certain bulk drug substances that may present significant safety risks. BPC-157 row, "nominated but withdrawn."

4. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding (Category 1 list). Version updated May 14, 2026; checked October 15, 2026.

5. Electronic Code of Federal Regulations. 21 CFR 216.23. Displayed as up to date through October 13, 2026.

6. U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting.

7. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A.

8. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers.

9. U.S. Food and Drug Administration. Understanding unapproved use of approved drugs "off label".

10. U.S. Food and Drug Administration. Locate a state-licensed online pharmacy.

11. U.S. Food and Drug Administration. Personal importation.

12. U.S. Department of Health and Human Services. Telehealth licensure.

13. Orrick, Herrington & Sutcliffe. FDA announces removal of 12 peptides from Category 2. April 16, 2026.

14. ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. July 23, 2026.

15. RAPS. FDA advisory committee backs two controversial peptides. July 2026.

16. Becker's Hospital Review. HHS plans stopgap to allow sales of some unapproved peptides: Washington Post. October 2026.

17. KFF Health News. Reporting on experimental peptides and patient harms. October 13, 2026; checked October 15, 2026.

18. ClinicalTrials.gov: NCT07803250, NCT07437547, NCT07752381, NCT02637284. Checked October 15, 2026.

19. Lee E, Padgett B. Intra-articular injection of BPC-157 for multiple types of knee pain. 2021. Checked October 15, 2026.

20. Lee E, Burgess K. Intravenous BPC-157 pilot. 2025. Checked October 15, 2026.

21. Venkatakrishnan AJ and colleagues. Rising use of unapproved BPC-157 and patient-reported outcomes curated from clinical notes. Preprint v1, September 7, 2026; not peer-reviewed when checked October 15, 2026.

22. World Anti-Doping Agency. Prohibited List.

23. Clinic pages (provider-published): Robertson Wellness & Aesthetics; Revived Personalized Wellness; Endocrinology Associates BPC-157 page and pricing page; Back On Point Wellness peptide page and recovery peptides page; Spencer Wellness Centre; Modern Wellness Clinic and partner pharmacies.

24. Rx Peps Direct. BPC-157 advertised offer; Refund and Cancellation Policy, June 2026; Terms of Service, March 2026. Read October 15, 2026; no checkout or patient-specific fill confirmed.

25. Eagle Analytical Services. Provider-hosted report ETX-260727-0539, lot LG342009607, testing completed July 31, 2026. PDF visually inspected October 15; not authenticated with the issuer.

26. Modern Wellness Clinic. Return policy. Read October 15, 2026; separate from a pharmacy-specific never-filled order refund determination.

27. The Lab Aesthetics & Wellness. Peptide price menu. Separate Spokane price example; read October 15, 2026.

28. U.S. Food and Drug Administration. 503B bulk-substance framework; considering an online pharmacy; expanded access information for patients. Read October 15, 2026.

29. Federation of State Medical Boards. State medical-board directory. National Council of State Boards of Nursing. Nursys overview. Lookup routes inspected October 15, 2026; no individual license check performed.

30. World Anti-Doping Agency. 2027 Prohibited List, effective January 1, 2027; BPC-157 on page 4. Relevant PDF pages visually inspected October 15, 2026.

31. Federal Register. Exact-phrase BPC-157 API search. October 15, 2026 result: one April 16 meeting notice. This specific search did not return a proposed or final addition rule.